ESLA (Estrella Immunopharma) Current Accrued Expense: $8.49 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ESLA Estrella Immunopharma Inc ESLA
12 GF Score
Price $0.71
! 1 Warning Sign
View Full Analysis

What is Estrella Immunopharma Current Accrued Expense?

Estrella Immunopharma ESLA -1.11% 12 Current Accrued Expense is $8.49 Mil as of Jun. 2026. GuruFocus rates ESLA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Estrella Immunopharma's Current Accrued Expense for the quarter that ended in Jun. 2026 was $8.49 Mil.

Estrella Immunopharma's quarterly Current Accrued Expense declined from Dec. 2025 ($12.56 Mil) to Mar. 2026 ($8.44 Mil) but then increased from Mar. 2026 ($8.44 Mil) to Jun. 2026 ($8.49 Mil).

Estrella Immunopharma's annual Current Accrued Expense declined from Jun. 2023 ($0.42 Mil) to Jun. 2024 ($0.13 Mil) but then increased from Jun. 2024 ($0.13 Mil) to Dec. 2025 ($12.56 Mil).

Estrella Immunopharma Current Accrued Expense Related Terms

Estrella Immunopharma Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Estrella Immunopharma's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Estrella Immunopharma Current Accrued Expense Chart

Estrella Immunopharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Dec25
Current Accrued Expense
0.00 0.00 0.42 0.13 12.56

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.87 12.97 12.56 8.44 8.49
ESLA
12GF Score
Estrella Immunopharma Inc ESLA
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Estrella Immunopharma Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $8.49 Mil mean?
Estrella Immunopharma (ESLA) has a Current Accrued Expense of $8.49 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Estrella Immunopharma and its competitors.
Is Estrella Immunopharma's Current Accrued Expense too high?
Estrella Immunopharma's current Current Accrued Expense is $8.49 Mil. Overall, Estrella Immunopharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Estrella Immunopharma's Current Accrued Expense compare to LITS and NNVC?
Estrella Immunopharma's Current Accrued Expense of $8.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Estrella Immunopharma and its competitors. Estrella Immunopharma's current Current Accrued Expense is $8.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Estrella Immunopharma stock overvalued right now?
Estrella Immunopharma (ESLA) has a current Current Accrued Expense of $8.49 Mil. The current Current Accrued Expense is $8.49 Mil. Estrella Immunopharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Estrella Immunopharma (ESLA), the current Current Accrued Expense is $8.49 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Estrella Immunopharma Business Description

Address 5858 Horton Street, Suite 370, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
12GF Score

Get the complete analysis for ESLA

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price